×

Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2

  • US 8,859,515 B2
  • Filed: 06/24/2010
  • Issued: 10/14/2014
  • Est. Priority Date: 06/24/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method of upregulating a function of and/or the expression of a Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide having SEQ ID NO:

  • 1 in human patient cells or tissues in vivo or in vitro comprising;

    contacting said cells or tissues with at least one antisense oligonucleotide 16 to 26 nucleotides in length wherein said at least one oligonueleotide has at least 80% sequence identity to a reverse complement of a polynueleotide comprising 10 to 30 consecutive nucleotides within nucleotides 1 to 413 of SEQ ID NO;

    2 and 1 to 413 of SEQ ID NO;

    3;

    thereby upregulating a function of and/or the expression of the Tumor Necrosis Factor Receptor 2 (TNFR2) polynucleotide in patient cells or tissues in vivo or in vitro.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×